Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 10/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bmy-7378 SCHEMBL32690868 | 1.00 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| Bmy-7378 SCHEMBL987183 | 0.99 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL10521435 | 0.86 | HTR1A (0.75) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| Hydrochloric Acid SCHEMBL10517891 | 0.85 | HTR1A (0.76) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL14416822 | 0.85 | HTR1A (0.78) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL7655340 | 0.84 | HTR1A (0.85) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL10517262 | 0.84 | HTR1A (0.76) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| Hydrochloric Acid SCHEMBL7655300 | 0.83 | HTR1A (0.83) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL6751064 | 0.82 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL10658613 | 0.80 | HTR1A (0.70) | HTR1AADRA1BADRA1AADRA1DDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| US-20180028499-A1 | 5HT AGONISTS FOR TREATING DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-02-01 | — | — | US | claimed |
| EP-3261640-A1 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of The University of California (US) | 2018-01-03 | — | — | EP | claimed |
| WO-2016138138-A1 | 5HT AGONISTS FOR TREATING DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-01 | — | — | WO | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| WO-2005032594-A2 | ALKYLATORS LINKED TO POLYAMIDES AS DNA BINDING AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | claimed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| US-20020035998-A1 | Method for treatment of cancer and infectious disease | HELLSTRAND KRISTOFFER (SE) | 2002-03-28 | — | — | US | claimed |
| US-6305380-B1 | ADMINISTERING HISTAMINE AGONIST OR HT3 RECEPTOR ANTAGONIST TO ACTIVATE NATURAL KILLER CELLS AND TREAT VIRAL DISEASES | MAXIM PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | claimed |
| EP-0652768-B1 | A pharmaceutical preparation for the synergistic activation of natural killer cells | MAXIM PHARM INC (US) | 2000-05-03 | — | — | EP | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-6003516-A | Method for treatment of cancer and infectious disease | MAXIM PHARMACEUTICALS, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0555446-B1 | USE OF ANTAGONISTS OR PARTIAL AGONISTS ON THE 5-HT 1a RECEPTOR FOR THE TREATMENT AND PREVENTION OF COGNITIVE DISORDERS | BAYER AG (DE) | 1999-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | SLC6A4, SLC6A2, TPH2 | HTR1A 10/4885ADRA1B 193/4885ADRA1A 255/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | HTR1A 6/4885ADRA1B 814/4885ADRA1A 1120/4885 |
| US-20180028499-A1 | 5HT AGONISTS FOR TREATING DISORDERS | HTR1A, HTR5A, HTR2A | HTR1A 1/4885ADRA1B 130/4885ADRA1A 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.